$AEMD
AETHLON MEDICAL INC

2024 Q4 Form 10-Q Financial Statement

#000168316824007984 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $261.5K
YoY Change -58.39%
% of Gross Profit
Depreciation & Amortization $85.83K
YoY Change -4.63%
% of Gross Profit
Operating Expenses $2.902M
YoY Change -8.6%
Operating Profit -$2.902M
YoY Change -8.6%
Interest Expense $95.15K
YoY Change -32.04%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.807M
YoY Change -7.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.20
COMMON SHARES
Basic Shares Outstanding 13.96M shares 13.94M shares
Diluted Shares Outstanding 13.94M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.859M
YoY Change -32.62%
Cash & Equivalents $6.859M
Short-Term Investments
Other Short-Term Assets $279.0K
YoY Change -10.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.138M
YoY Change -31.94%
LONG-TERM ASSETS
Property, Plant & Equipment $843.6K
YoY Change -29.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $120.8K
YoY Change 0.68%
Total Long-Term Assets $1.709M
YoY Change -26.99%
TOTAL ASSETS
Total Short-Term Assets $7.138M
Total Long-Term Assets $1.709M
Total Assets $8.847M
YoY Change -31.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $922.9K
YoY Change 34.74%
Accrued Expenses $1.258M
YoY Change 22.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.331M
YoY Change 36.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $496.8K
YoY Change -37.9%
Total Long-Term Liabilities $496.8K
YoY Change -37.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.331M
Total Long-Term Liabilities $496.8K
Total Liabilities $2.828M
YoY Change 12.72%
SHAREHOLDERS EQUITY
Retained Earnings -$159.9M
YoY Change 7.58%
Common Stock $13.96K
YoY Change 460.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.019M
YoY Change
Total Liabilities & Shareholders Equity $8.847M
YoY Change -31.03%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.807M
YoY Change -7.5%
Depreciation, Depletion And Amortization $85.83K
YoY Change -4.63%
Cash From Operating Activities -$2.215M
YoY Change -18.28%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.830K
YoY Change -61.7%
NET CHANGE
Cash From Operating Activities -2.215M
Cash From Investing Activities 0.000
Cash From Financing Activities -3.830K
Net Change In Cash -2.218M
YoY Change -18.74%
FREE CASH FLOW
Cash From Operating Activities -$2.215M
Capital Expenditures $0.00
Free Cash Flow -$2.215M
YoY Change -18.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
628447 usd
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-37487
dei Entity Registrant Name
EntityRegistrantName
Aethlon Medical, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3632859
dei Entity Address Address Line1
EntityAddressAddressLine1
11555 SORRENTO VALLEY ROAD
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 203
dei Entity Address City Or Town
EntityAddressCityOrTown
SAN DIEGO
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
619
dei Local Phone Number
LocalPhoneNumber
941-0360
dei Security12b Title
Security12bTitle
COMMON STOCK, $0.001 PAR VALUE
dei Trading Symbol
TradingSymbol
AEMD
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5441978 usd
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
7138083 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
6225788 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
843617 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1015229 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
743994 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
883054 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
825 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1100 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
87506 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
87506 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
496772 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
649751 usd
CY2024Q3 us-gaap Liabilities
Liabilities
2828222 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2479650 usd
us-gaap Share Based Compensation
ShareBasedCompensation
507295 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000882291
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 aemd Stock Issued During Period Value Rounding For Reverse Split
StockIssuedDuringPeriodValueRoundingForReverseSplit
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13961998 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6859075 usd
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
277827 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
279008 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
505983 usd
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
33305 usd
CY2024Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
33305 usd
CY2024Q3 us-gaap Assets
Assets
8847330 usd
CY2024Q1 us-gaap Assets
Assets
8245982 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
922888 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
777862 usd
CY2024Q3 aemd Due To Related Parties
DueToRelatedParties
1011544 usd
CY2024Q1 aemd Due To Related Parties
DueToRelatedParties
546434 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
301680 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
290565 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
95338 usd
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
215038 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2331450 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1829899 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13961998 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13961998 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2629725 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2629725 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
13962 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
2629 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165954256 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
160337371 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3969 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6940 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159945141 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154566728 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6019108 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
5766332 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8847330 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8245982 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
570845 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
1133111 usd
us-gaap Professional Fees
ProfessionalFees
1184927 usd
us-gaap Professional Fees
ProfessionalFees
2109749 usd
CY2024Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1372899 usd
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1191426 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
2627701 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
2314665 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
958375 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
850809 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1709228 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2159092 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2902119 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3175346 usd
us-gaap Operating Expenses
OperatingExpenses
5521856 usd
us-gaap Operating Expenses
OperatingExpenses
6583506 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2902119 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3175346 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5521856 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6583506 usd
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
95146 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
140890 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
143442 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
266871 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2806973 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3034456 usd
us-gaap Net Income Loss
NetIncomeLoss
-5378414 usd
us-gaap Net Income Loss
NetIncomeLoss
-6316635 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-3804 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
2435 usd
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-2971 usd
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
3429 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
2803169 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
3036891 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
5375443 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
6320064 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.57
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13937595 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13937595 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2483649 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2483649 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10715446 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10715446 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2457711 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2457711 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
5766332 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
5766332 usd
CY2024Q2 aemd Issuances Of Common Stock For Public Offering
IssuancesOfCommonStockForPublicOffering
3539907 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1844400 usd
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-5078 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
139328 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-2571440 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-833 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
8712616 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
8712616 usd
CY2024Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-3832 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
113493 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2806973 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3804 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6019108 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6019108 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15064209 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15064209 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1086119 usd
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-8372 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
250114 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-3282179 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-994 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13108897 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13108897 usd
CY2023Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-9843 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
257181 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3034456 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2435 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10319344 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10319344 usd
us-gaap Net Income Loss
NetIncomeLoss
-5378414 usd
us-gaap Net Income Loss
NetIncomeLoss
-6316635 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
171887 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
181752 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
252821 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
507295 usd
aemd Accretion Of Rightofuse Operating Lease Asset
AccretionOfRightofuseOperatingLeaseAsset
-139060 usd
aemd Accretion Of Rightofuse Operating Lease Asset
AccretionOfRightofuseOperatingLeaseAsset
-1924 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-292071 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-241411 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
95370 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
162160 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
465110 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
35560 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3962095 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5186533 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
237153 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-237153 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5384307 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1086119 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8910 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
18215 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5375397 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1067904 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3795 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1241 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1417097 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4357023 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5529484 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14620449 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6946581 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10263426 usd
aemd Par Value Of Shares Issued For Vested Restricted Stock Units And Net Stock Option Exercise
ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise
53 usd
aemd Par Value Of Shares Issued For Vested Restricted Stock Units And Net Stock Option Exercise
ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise
16 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6859075 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10175920 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
87506 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
87506 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6946581 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10263426 usd
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_zDTFRhL9iF31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86F_zatSXlBA1hDf">Basis of Presentation and Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission (“SEC”) Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2024, included in our Annual Report on Form 10-K filed with the SEC on June 27, 2024. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements, taken as a whole, contain all adjustments that are of a normal recurring nature necessary to present fairly our operating results, cash flows, and financial position as of and for the period ended September 30, 2024. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2024 has been derived from the audited consolidated balance sheet at March 31, 2024, contained in the above referenced 10-K. The results of operations for the three and six months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any future interim periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4rHfFJiNAo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zxRlCGVwFwo6">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation, including the impact of the reverse stock split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159945141 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13521135 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
221839 shares
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
261486 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
702115 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1687010 usd
CY2024Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1844400 usd
CY2024Q3 aemd Due To Related Parties
DueToRelatedParties
1011544 usd
CY2024Q1 aemd Due To Related Parties
DueToRelatedParties
546434 usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
113493 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
257181 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
252821 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
507295 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
113493 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
257181 usd
us-gaap Share Based Compensation
ShareBasedCompensation
252821 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13937595 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13937595 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2483649 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2483649 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10715446 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10715446 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2457711 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2457711 shares
us-gaap Share Based Compensation
ShareBasedCompensation
252821 usd
us-gaap Share Based Compensation
ShareBasedCompensation
507295 usd
aemd Change In Earnings Per Share Basic
ChangeInEarningsPerShareBasic
-0.02
aemd Change In Earnings Per Share Diluted
ChangeInEarningsPerShareDiluted
-0.02
aemd Change In Earnings Per Share Basic
ChangeInEarningsPerShareBasic
-0.21
aemd Change In Earnings Per Share Diluted
ChangeInEarningsPerShareDiluted
-0.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2024Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.47
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
28653 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
8778 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
5032 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0.83
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
14843 shares
us-gaap Share Based Compensation
ShareBasedCompensation
252821 usd
us-gaap Share Based Compensation
ShareBasedCompensation
507295 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
0.47
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
305677 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P0Y11M15D
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
743994 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
798452 usd
CY2024Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
87506 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
108000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
105000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
210000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
210000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-007984-index-headers.html Edgar Link pending
0001683168-24-007984-index.html Edgar Link pending
0001683168-24-007984.txt Edgar Link pending
0001683168-24-007984-xbrl.zip Edgar Link pending
aemd-20240930.xsd Edgar Link pending
aethlon_ex3101.htm Edgar Link pending
aethlon_ex3201.htm Edgar Link pending
aethlon_i10q-093024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
aemd-20240930_cal.xml Edgar Link unprocessable
aemd-20240930_def.xml Edgar Link unprocessable
aemd-20240930_lab.xml Edgar Link unprocessable
aemd-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aethlon_i10q-093024_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending